BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23516248)

  • 1. A model of dendritic cell therapy for melanoma.
    Depillis L; Gallegos A; Radunskaya A
    Front Oncol; 2013; 3():56. PubMed ID: 23516248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model.
    Castillo-Montiel E; Chimal-Eguía JC; Tello JI; Piñon-Zaráte G; Herrera-Enríquez M; Castell-Rodríguez AE
    Theor Biol Med Model; 2015 Jun; 12():11. PubMed ID: 26054860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic Immunotherapy Improvement for an Optimal Control Murine Model.
    Rangel-Reyes JC; Chimal-Eguía JC; Castillo-Montiel E
    Comput Math Methods Med; 2017; 2017():5291823. PubMed ID: 28912828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CART
    Barros LRC; Paixão EA; Valli AMP; Naozuka GT; Fassoni AC; Almeida RC
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice.
    Triozzi PL; Aldrich W; Achberger S; Ponnazhagan S; Alcazar O; Saunthararajah Y
    Cancer Immunol Immunother; 2012 Sep; 61(9):1441-50. PubMed ID: 22310929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFNα and 5-Aza-2'-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model.
    Gordy JT; Sandhu AK; Fessler K; Luo K; Kapoor AR; Ayeh SK; Hui Y; Schill C; Chen F; Wang T; Karanika S; Sunshine JC; Karakousis PC; Markham RB
    Front Immunol; 2022; 13():1074644. PubMed ID: 36741387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol.
    Qomlaqi M; Bahrami F; Ajami M; Hajati J
    Math Biosci; 2017 Oct; 292():1-9. PubMed ID: 28713023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agent-based Modeling of Tumor and Immune System Interactions in Combinational Therapy with Low-dose 5-fluorouracil and Dendritic Cell Vaccine in Melanoma B16F10.
    Rahbar S; Shafiekhani S; Allahverdi A; Jamali A; Kheshtchin N; Ajami M; Mirsanei Z; Habibi S; Makkiabadi B; Hadjati J; Jafari AH
    Iran J Allergy Asthma Immunol; 2022 Apr; 21(2):151-166. PubMed ID: 35490269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.
    Tan C; Reddy V; Dannull J; Ding E; Nair SK; Tyler DS; Pruitt SK; Lee WT
    J Transl Med; 2013 Jun; 11():148. PubMed ID: 23768240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
    Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
    Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.
    Gleisner MA; Pereda C; Tittarelli A; Navarrete M; Fuentes C; Ávalos I; Tempio F; Araya JP; Becker MI; González FE; López MN; Salazar-Onfray F
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.
    Yu J; Tian R; Xiu B; Yan J; Jia R; Zhang L; Chang AE; Song H; Li Q
    Int J Biol Sci; 2009; 5(2):135-46. PubMed ID: 19173035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICAM2 is related to good prognosis in dendritic cell immunotherapy for cancer.
    da Silva SF; Murta EF; Michelin MA
    Immunotherapy; 2024 Feb; 16(3):173-185. PubMed ID: 38126167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines.
    Węgierek-Ciura K; Mierzejewska J; Szczygieł A; Rossowska J; Wróblewska A; Świtalska M; Goszczyński TM; Szermer-Olearnik B; Pajtasz-Piasecka E
    Front Immunol; 2023; 14():1212606. PubMed ID: 37545526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.